Selected research
Industry Research
Kidney Cancer Treatment Drugs Industry Research Report 2026
Market perspective
The global Kidney Cancer Treatment Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Kidney Cancer Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Kidney Cancer Treatment Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Kidney Cancer Treatment Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Kidney Cancer Treatment Drugs include Eisai, Novartis, Merck, Roche, Pfizer, Bayer, AstraZeneca, Prometheus Labs and Incyte, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Kidney Cancer Treatment Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Kidney Cancer Treatment Drugs Market by Company
Eisai
Novartis
Merck
Roche
Pfizer
Bayer
AstraZeneca
Prometheus Labs
Incyte
Exelixis
Bristol-Myers Squibb
Aveo Pharmaceuticals
Argos Therapeutics
Amgen/Allergan
Kidney Cancer Treatment Drugs Segment by Type
Angiogenesis Inhibitors
Cytokine Immunotherapy (IL-2)
Monoclonal Antibodies
mTOR Inhibitors
Kidney Cancer Treatment Drugs Segment by Application
Research Institutes
Hospitals
Diagnostic Centers
Others
Kidney Cancer Treatment Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Treatment Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Kidney Cancer Treatment Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Kidney Cancer Treatment Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Kidney Cancer Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Angiogenesis Inhibitors
- Cytokine Immunotherapy (IL-2)
- Monoclonal Antibodies
- mTOR Inhibitors
Applications
- Research Institutes
- Hospitals
- Diagnostic Centers
- Others
Companies covered
- Eisai
- Novartis
- Merck
- Roche
- Pfizer
- Bayer
- AstraZeneca
- Prometheus Labs
- Incyte
- Exelixis
- Bristol-Myers Squibb
- Aveo Pharmaceuticals
- Argos Therapeutics
- Amgen/Allergan
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Kidney Cancer Treatment Drugs Market Size (2021-2032)
- 2.2.2 Global Kidney Cancer Treatment Drugs Sales (2021-2032)
- 2.2.3 Global Kidney Cancer Treatment Drugs Market Average Price (2021-2032)
- 2.3 Kidney Cancer Treatment Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Angiogenesis Inhibitors
- 2.3.3 Cytokine Immunotherapy (IL-2)
- 2.3.4 Monoclonal Antibodies
- 2.3.5 mTOR Inhibitors
- 2.4 Kidney Cancer Treatment Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Research Institutes
- 2.4.3 Hospitals
- 2.4.4 Diagnostic Centers
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Kidney Cancer Treatment Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Kidney Cancer Treatment Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Kidney Cancer Treatment Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Kidney Cancer Treatment Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Kidney Cancer Treatment Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Kidney Cancer Treatment Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Kidney Cancer Treatment Drugs, Product Type & Application
- 3.8 Global Manufacturers of Kidney Cancer Treatment Drugs, Established Date
- 3.9 Global Kidney Cancer Treatment Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eisai
- 4.1.1 Eisai Company Information
- 4.1.2 Eisai Business Overview
- 4.1.3 Eisai Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eisai Kidney Cancer Treatment Drugs Product Portfolio
- 4.1.5 Eisai Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Kidney Cancer Treatment Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Kidney Cancer Treatment Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Roche
- 4.4.1 Roche Company Information
- 4.4.2 Roche Business Overview
- 4.4.3 Roche Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Roche Kidney Cancer Treatment Drugs Product Portfolio
- 4.4.5 Roche Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Kidney Cancer Treatment Drugs Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Kidney Cancer Treatment Drugs Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Kidney Cancer Treatment Drugs Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Prometheus Labs
- 4.8.1 Prometheus Labs Company Information
- 4.8.2 Prometheus Labs Business Overview
- 4.8.3 Prometheus Labs Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Prometheus Labs Kidney Cancer Treatment Drugs Product Portfolio
- 4.8.5 Prometheus Labs Recent Developments
- 4.9 Incyte
- 4.9.1 Incyte Company Information
- 4.9.2 Incyte Business Overview
- 4.9.3 Incyte Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Incyte Kidney Cancer Treatment Drugs Product Portfolio
- 4.9.5 Incyte Recent Developments
- 4.10 Exelixis
- 4.10.1 Exelixis Company Information
- 4.10.2 Exelixis Business Overview
- 4.10.3 Exelixis Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Exelixis Kidney Cancer Treatment Drugs Product Portfolio
- 4.10.5 Exelixis Recent Developments
- 4.11 Bristol-Myers Squibb
- 4.11.1 Bristol-Myers Squibb Company Information
- 4.11.2 Bristol-Myers Squibb Business Overview
- 4.11.3 Bristol-Myers Squibb Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bristol-Myers Squibb Kidney Cancer Treatment Drugs Product Portfolio
- 4.11.5 Bristol-Myers Squibb Recent Developments
- 4.12 Aveo Pharmaceuticals
- 4.12.1 Aveo Pharmaceuticals Company Information
- 4.12.2 Aveo Pharmaceuticals Business Overview
- 4.12.3 Aveo Pharmaceuticals Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Aveo Pharmaceuticals Kidney Cancer Treatment Drugs Product Portfolio
- 4.12.5 Aveo Pharmaceuticals Recent Developments
- 4.13 Argos Therapeutics
- 4.13.1 Argos Therapeutics Company Information
- 4.13.2 Argos Therapeutics Business Overview
- 4.13.3 Argos Therapeutics Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Argos Therapeutics Kidney Cancer Treatment Drugs Product Portfolio
- 4.13.5 Argos Therapeutics Recent Developments
- 4.14 Amgen/Allergan
- 4.14.1 Amgen/Allergan Company Information
- 4.14.2 Amgen/Allergan Business Overview
- 4.14.3 Amgen/Allergan Kidney Cancer Treatment Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Amgen/Allergan Kidney Cancer Treatment Drugs Product Portfolio
- 4.14.5 Amgen/Allergan Recent Developments
5 Global Kidney Cancer Treatment Drugs Market Scenario by Region
- 5.1 Global Kidney Cancer Treatment Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Kidney Cancer Treatment Drugs Sales by Region: 2021-2032
- 5.2.1 Global Kidney Cancer Treatment Drugs Sales by Region: 2021-2026
- 5.2.2 Global Kidney Cancer Treatment Drugs Sales by Region: 2027-2032
- 5.3 Global Kidney Cancer Treatment Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Kidney Cancer Treatment Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Kidney Cancer Treatment Drugs Revenue by Region: 2027-2032
- 5.4 North America Kidney Cancer Treatment Drugs Market Facts & Figures by Country
- 5.4.1 North America Kidney Cancer Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Kidney Cancer Treatment Drugs Sales by Country (2021-2032)
- 5.4.3 North America Kidney Cancer Treatment Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Kidney Cancer Treatment Drugs Market Facts & Figures by Country
- 5.5.1 Europe Kidney Cancer Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Kidney Cancer Treatment Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Kidney Cancer Treatment Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Kidney Cancer Treatment Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Kidney Cancer Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Kidney Cancer Treatment Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Kidney Cancer Treatment Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Kidney Cancer Treatment Drugs Market Facts & Figures by Country
- 5.7.1 South America Kidney Cancer Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Kidney Cancer Treatment Drugs Sales by Country (2021-2032)
- 5.7.3 South America Kidney Cancer Treatment Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Kidney Cancer Treatment Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Kidney Cancer Treatment Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Kidney Cancer Treatment Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Kidney Cancer Treatment Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Kidney Cancer Treatment Drugs Sales by Type (2021-2032)
- 6.1.1 Global Kidney Cancer Treatment Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Kidney Cancer Treatment Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Kidney Cancer Treatment Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Kidney Cancer Treatment Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Kidney Cancer Treatment Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Kidney Cancer Treatment Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Kidney Cancer Treatment Drugs Sales by Application (2021-2032)
- 7.1.1 Global Kidney Cancer Treatment Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Kidney Cancer Treatment Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Kidney Cancer Treatment Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Kidney Cancer Treatment Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Kidney Cancer Treatment Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Kidney Cancer Treatment Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Kidney Cancer Treatment Drugs Value Chain Analysis
- 8.1.1 Kidney Cancer Treatment Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Kidney Cancer Treatment Drugs Production Mode & Process
- 8.2 Kidney Cancer Treatment Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Kidney Cancer Treatment Drugs Distributors
- 8.2.3 Kidney Cancer Treatment Drugs Customers
9 Global Kidney Cancer Treatment Drugs Analyzing Market Dynamics
- 9.1 Kidney Cancer Treatment Drugs Industry Trends
- 9.2 Kidney Cancer Treatment Drugs Industry Drivers
- 9.3 Kidney Cancer Treatment Drugs Industry Opportunities and Challenges
- 9.4 Kidney Cancer Treatment Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst